vTv Therapeutics Statistics
Share Statistics
vTv Therapeutics has 3.19M shares outstanding. The number of shares has increased by 19.43% in one year.
| Shares Outstanding | 3.19M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 1.48M |
| Failed to Deliver (FTD) Shares | 959 |
| FTD / Avg. Volume | 2.93% |
Short Selling Information
The latest short interest is 28.85K, so 0.9% of the outstanding shares have been sold short.
| Short Interest | 28.85K |
| Short % of Shares Out | 0.9% |
| Short % of Float | 1.71% |
| Short Ratio (days to cover) | 1.5 |
Valuation Ratios
The PE ratio is -1.18 and the forward PE ratio is -42.15.
| PE Ratio | -1.18 |
| Forward PE | -42.15 |
| PS Ratio | 0 |
| Forward PS | null |
| PB Ratio | -0.97 |
| P/FCF Ratio | -1.26 |
| PEG Ratio | n/a |
Enterprise Valuation
vTv Therapeutics Inc. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 1, with a Debt / Equity ratio of -0.01.
| Current Ratio | 1 |
| Quick Ratio | 1 |
| Debt / Equity | -0.01 |
| Total Debt / Capitalization | -1.48 |
| Cash Flow / Debt | -53 |
| Interest Coverage | -1961.69 |
Financial Efficiency
Return on equity (ROE) is 0.82% and return on capital (ROIC) is 141.52%.
| Return on Equity (ROE) | 0.82% |
| Return on Assets (ROA) | -1.84% |
| Return on Capital (ROIC) | 141.52% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -1.27M |
| Employee Count | 16 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 71.77% in the last 52 weeks. The beta is 0.63, so vTv Therapeutics 's price volatility has been higher than the market average.
| Beta | 0.63 |
| 52-Week Price Change | 71.77% |
| 50-Day Moving Average | 14.93 |
| 200-Day Moving Average | 18.62 |
| Relative Strength Index (RSI) | 46.15 |
| Average Volume (20 Days) | 32.78K |
Income Statement
In the last 12 months, vTv Therapeutics had revenue of $0 and earned -$20.25M in profits. Earnings per share was $-9.71.
| Revenue | 0 |
| Gross Profit | -13.60M |
| Operating Income | -25.50M |
| Net Income | -20.25M |
| EBITDA | -25.41M |
| EBIT | - |
| Earnings Per Share (EPS) | -9.71 |
Balance Sheet
The company has $9.45M in cash and $529.00K in debt, giving a net cash position of $8.92M.
| Cash & Cash Equivalents | 9.45M |
| Total Debt | 529.00K |
| Net Cash | 8.92M |
| Retained Earnings | -281.04M |
| Total Assets | 43.16M |
| Working Capital | 36.53M |
Cash Flow
In the last 12 months, operating cash flow was -$19.08M and capital expenditures $0, giving a free cash flow of -$19.08M.
| Operating Cash Flow | -19.08M |
| Capital Expenditures | 0 |
| Free Cash Flow | -19.08M |
| FCF Per Share | -9.15 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
VTVT does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -64.6% |
| FCF Yield | -39.8% |
Analyst Forecast
The average price target for VTVT is $35, which is 132.9% higher than the current price. The consensus rating is "Buy".
| Price Target | $35 |
| Price Target Difference | 132.9% |
| Analyst Consensus | Buy |
| Analyst Count | 1 |
Stock Splits
The last stock split was on Nov 21, 2023. It was a backward split with a ratio of 1:40.
| Last Split Date | Nov 21, 2023 |
| Split Type | backward |
| Split Ratio | 1:40 |
Scores
| Altman Z-Score | -9.25 |
| Piotroski F-Score | 2 |